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The present studies were aimed at investigating the
possible roles of dopamine (DA) and iron in production
of hydroxyl radicals (·OH) in rat striatum after Mn21
intoxication. For this purpose, DA depletions were
assessed concomitant with in vivo 2,3- and 2,5-dihy-
droxybenzoic acid (DHBA) formation from the reac-
tion of salicylate with ·OH, of which 2,3-DHBA is a
nonenzymatic adduct. Following intrastriatal Mn21
injection, marked 2,3-DHBA increases were observed
in a time- and dose-dependent fashion reaching maxi-
mum levels at 6–18 h and a plateau beyond 0.4 mmol
(fourfold increase). The delayed increase of 2,3-DHBA
levels suggests that Mn21 induces ·OH formation in the
living brain by an indirect process. The early DA
depletion (2 h) and relatively late ·OH formation (6 h)
indicate independent processes by Mn21. In addition,
depletion of DA (about 90%) by reserpine pretreatment
did not significantly alter Mn21-induced 2,3-DHBA for-
mation or the extent of DA depletion, suggesting that
DA or DA autoxidation are not participating in Mn21-
induced ·OH formation in vivo. Furthermore, Mn21
injection did not significantly alter the low molecular
weight iron pool in striatum, and co-injections of the
iron-chelator deferoxamine with Mn21 into striatum
did not significantly attenuateMn21-induced 2,3-DHBA
formation. These findings suggest no role of chelatable
iron in generation of Mn21-induced ·OH, but do not
exclude a role for mitochondrial heme–iron or peroxy-
nitrite (Fe-independent) in Mn21-induced ·OH forma-
tion. r 1996Academic Press, Inc.
INTRODUCTION
Chronic inhalation of manganese (Mn) dust or vapor
in humans and monkeys causes parkinsonism and
dystonia (3, 4, 17) and produces selective neuropathol-
ogy in the basal ganglia with lesions being localized
both pre- and postsynaptically to the dopaminergic
(DA) nigrostriatal pathway (8, 19–21, 62, 63). In addi-
tion, Mn21 injection into the basal ganglia of rats (8, 40,
46, 47, 54) provides a model of chronic systemic Mn
exposure in humans. For more than a decade, it has
been hypothesized from in vitro studies that Mn neuro-
toxicity is mediated by free radicals via enhanced
nonenzymatic autoxidation of catecholamines (1, 26,
27, 30, 42) or production of 6-hydroxydopamine (6-
OHDA) (12, 13, 23). Both processes would lead to
production of toxic (semi)quinones and enhanced levels
of H2O2 and superoxide anion radicals (O2·2) as well as
hydroxyl radicals (·OH). This concept is in agreement
with attenuation of Mn21-induced DA depletion by
vitamin E treatment (48). On the other hand, it has
been reported that lipid peroxidation is inhibited by
Mn21 both in vitro (11, 60) and in postmortem brain
tissues of Mn21-exposed rats (16, 53). In addition, in
vitro studies have shown that Mn produces irreversible
DA depletion by oxidation to quinones without the
formation of reactive oxygen species (1, 51).
Although production of (semi)quinones or free oxy-
gen radicals after Mn has not been reported in vivo, it
seems likely that DA plays a role in Mn neurotoxicity.
For instance, pretreatment with the DA synthesis
blockers a-methyltyrosine and lisuride attenuates the
neurotoxicity of Mn21 (47), whereas the monoamine
oxidase inhibitor pargyline and L-DOPA (1carbidopa)
potentiate its toxicity (46).
Besides DA, brain iron could mediate neurotoxic
effects of Mn21. The selective accumulation of Mn21 in
the basal ganglia (19, 41, 45) and anterograde axonal
transport of Mn21 in nigrostriatal and striatonigral
neurons (55) may be dependent on iron transport and
storage pathways (2, 6, 32, 33, 44). In vitro studies have
shown that Mn binds to the iron transport protein
transferrin and its receptor on catecholamine-contain-
ing neuroblastoma cells and that Mn—like Fe—is
internalized followed by storage into ferritin (59). There-
fore, Mn21 may (in)directly liberate endogenous iron by
disturbing iron homeostasis, particularly in mitochon-
dria. In these organelles, Mn21 induces decreased glu-
thatione (GSH) contents and GSH enzyme activities
(38), thereby compromising a major cellular defense
mechanism against oxyradicals. In addition, Mn21 has
been reported to impair ATP production, decrease
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respiratory cytochrome contents, inhibit oxidative phos-
phorylation, and increase lactate production (9, 39, 25).
The aim of the present studies was twofold. First,
time- and dose-dependent ·OH formation by Mn21 was
assessed in relation to DA and serotonin (5-HT) deple-
tions in order to examine whether ·OH generation is
cause or consequence of brain damage. Like DA, 5-HT
levels are depleted by Mn within the choosen time span
of 24 h (54), which may significantly contribute to the
formation of both quinones and free oxyradicals (43). In
this study we used salicylate (SA) as an ·OH-trapping
agent, which forms the stable adducts 2,3- and 2,5-
dihydroxybenzoates (DHBA) (35, 56 and references
therein), and microinjections of Mn21 into rat striatum
as described previously (55). Since it has been reported
that 2,5-DHBA can also be formed via P450 enzymes,
which is not the case for 2,3-DHBA, the latter is a more
reliable index for ·OH formation (35). Second, the roles
of DA and iron in generating Mn21-induced ·OH forma-
tion were investigated by analyzing 2,3-DHBA levels in
striata of reserpine-pretreated (DA-depleted) or defer-
oxamine-treated (iron-chelated) rats, as well as by




Wistar-derived male rats (WAG, Harlan, Zeist, The
Netherlands) were kept on a 12/12-h light/dark cycle
and housed in a room with a humidity of 50–70% and a
temperature of 24°C with free access to water and chow
food. Animal experimentation protocols were approved
by the Ethical Committee for Laboratory Animals
Experiments, TNO/RegioWest (Woudenberg, TheNeth-
erlands, Reg. No. 56-3A).
Materials
MnCl2 (.96% pure), FeCl2 · 4H2O (.99% pure),
MgCl2 · 6H2O, and dopamine (3-hydroxytyramine · HCl)
were obtained from Merck (Darmstadt, Germany).
Solutions of metals were made as described previously
(55). All other compounds were purchased from Sigma
(Brunschwig Chemie, Amsterdam, The Netherlands)
and stored according to the description of the manufac-
turer.
Experimental Groups
Chloralhydrate-anesthetized (400mg/kg ip) rats (190–
230 g) received unilateral injections of MnCl2, FeCl2, or
MgCl2 in 1 µl of Milli-Q water (Millipore, Molsheim,
France) into striatum using stereotaxic procedures as
described previously (55).
DHBA formation by Mn: Time course and dose-
dependency. Two, six, or eighteen hours after intra-
striatal injection of 0.4 µmol Mn21, or 6 h after injection
of 0.4 µmol Mg21, rats (n 5 6–7 per group) were decapi-
tated to dissect striatal tissues from the brain. Like-
wise, rats (n 5 6–7 per dose) were injected with 0.13 or
1.20 µmol Mn21 6 h before collection of their striata. In
addition, 2 h prior to sacrifice, rats were loaded with
300 mg/kg SA (ip), whereas others (6–8 striata per
group) did not receive SA to serve as negative controls.
DHBA formation by Mn after dopamine depletion.
Eight rats were depleted of dopamine by 24-h pretreat-
ment with reserpine (10; 2.5 mg/kg ip). These rats
received a unilateral injection of 0.4 µmol Mn21 into
striatum andwere decapitated 6 h later. In addition, SA
(300 mg/kg ip) was given 2 h before sacrifice.
Effect of Mn on total and low molecular weight
(LMW) iron levels. Six hours after bilateral injection
of 0.4 µmol Mn21, Mg21, or Fe21 into striatum, rats
(n 5 4–8 per treatment) were decapitated and their
striata were dissected for immediate assay of total and
LMW iron contents.
Effect of deferoxamine onMn neurotoxicity. Ten rats
received an injection (1 µl total) of 0.4 µmol Mn21 plus
0.2 or 2.0 nmol deferoxamine mesylate (Desferal; DFX)
into the left striatum and 0.4 µmol NaCl plus DFX into
the right striatum. Six control rats received similar
bilateral injections without DFX. All rats were loaded
with SA (300mg/kg ip) and sacrificed respectively 4 and
6 h after stereotaxic injection.
Collection of Samples
Collection and handling of samples for analysis of
DA, 5-HT, SA, and related metabolites was done as
described previously (56). Briefly, dissected striatal
tissues (20–40 mg wet wt) were immediately frozen on
dry ice and stored at 270°C. At the day of analysis,
striata were sonicated in ice-cold 200 µl perchloric acid
containing Na2S2O5, centrifuged, diluted with mobile-
phase buffer, and kept on ice before injection into the
HPLC system.
For analysis of iron, freshly dissected striatal tissues
were immediately weighed in preweighed potter tubes,
homogenized in 100 mM Tris/HCl buffer (pH 7.4, 20%
w/v), and subsequently DFX (2 mM final concentration)
was added as described previously for heart tissue (61).
Depending on expected concentrations, striatal tissues
of 1 or 2 rats were pooled before homogenizing.
Analysis of 6-Hydroxydopamine, Dopamine, Serotonin,
Salicylate, and Related Metabolites
Levels of SA, 2,3- and 2,5-DHBA, as well as 6-OHDA,
DA, 5-HT, and theirmetabolites DOPAC (3,4-dihydroxy-
phenylacetic acid), HVA (4-hydroxy-3-methoxyphenyl-
acetic acid), and 5-HIAA(5-hydroxyindole-3-acetic acid)
were determined in striatal tissues according to a
previously described HPLC procedure with UV absor-
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bance and electrochemical detection (56). Since 6-OHDA
standards had a retention time between 2,3- and
2,5-DHBA standards, 6-OHDA measurements were
conducted in samples without SAwith a detection limit
of about 50 fmol. Briefly, a Spherisorb ODS2 cartridge
analytical column (100 3 4.6 mm, 3 µm) with a ODS1
precolumn (30 3 4.6 mm, 5 µm) (Phase Separation,
Ltd., Deeside, UK) was used to separate the compounds
of interest at a flow rate of 0.8 ml/min. The mobile-
phase buffer consisted of 0.1 M sodium acetate, 6.0%
methanol, 19.5 mg/liter n-octyl sodium sulfate (Merck,
Darmstadt, Germany), and 10–15mg/literNa2 ethylene-
diaminetetraacetate (EDTA) dissolved in Milli-Q water
and adjusted to pH 4.1 with glacial acetic acid. Stock
solutions of standards (,1 mM ) dissolved in 50 mM
HCl containing 0.20 g/liter Na2S2O5 and 0.050 g/liter
Na2EDTA were stable for at least 2 months if kept
stored in the dark at 4°C.
Analyses of Total and Low Molecular Weight Iron Pools
After centrifuging the striatal homogenate at 10,000g
for 15 min, the supernatant was removed for LMW iron
measurements in presence of the hexadentate iron
chelator DFX (61), which forms a strong complex with
iron: ferrioxamine (FX). LMW iron assays were con-
ducted under physiological or reducing conditions by
adding ascorbic acid (20 mg/ml in solid state). Ascorbic
acid was used to reduce iron from its ferric to its ferrous
state, thereby liberating iron from Fe31 complexes,
resulting in total LMW iron measurements. Briefly,
samples were incubated for 60min at 37°C and prepuri-
fied by passing them through a 50-mg Extract-Clean
C18 column (Alltech) on which DFX and FX are re-
tained. After washing with 0.3 ml water and elution
with 0.2 ml 90% methanol/10% water, the eluate was
injected into the HPLC system, which was equipped
with an ODS2 analytical column (as mentioned above)
and two variable wavelength detectors to allow simulta-
neous detection of FX at 430 nm and DFX at 229 nm
(Waters 484). Themobile phase consisted of 88% 20mM
Na2HPO4/NaH2PO4, 2 mMNaEDTA, 0.2M triethylam-
monium chloride (pH 6.6) and 12% acetonitrile. Recov-
ery of DFX and FX was respectively .80% and almost
100%. The detection limit for FX was 0.25 nmol. Iron
levels were based on FX/DFX ratios from FeSO4 stan-
dards incubated and extracted as the samples. Mn21
(100- to 800-fold excess) did not affect chelation of iron
by DFX in this procedure.
Total iron in the resuspended pellet (20% w/v in
Tris/HCl) was determined using the iron(II) chelator
Ferrozine essentially according to Riederer et al. (50).
Briefly, samples were added with Ferrozine (4.2 mM ),
ascorbic acid (20 mg/ml) to reduce iron, and pepsine
(0.1%) at a final pH of 2.5 using HCl. Subsequently,
samples were incubated at 37°C for 20 min, and
absorbances were read at 560 nm. Blank and standard
iron samples were treated in a similar manner. Mn21
did not affect chelation of iron by Ferrozine.
Statistics
Changes of the differences between ipsi- and contra-
lateral tissues over time or with increasing dose were
statistically evaluated using ANOVA (BMDP Statisti-
cal Software program SOLO, Los Angeles) followed by
Newman–Keuls multiple comparisons test. In addition,
the effect of time or dose in contra- or ipsilateral striata
were also tested. Differences between values of ipsi-
and contralateral tissues at the separate time points or
doses were evaluated using Student’s t test.
RESULTS
Time-Dependent Effects of 0.4 mmol Mn21
SA levels expressed as [ipsi-/contralateral] ratios
were significantly increased by Mn21 at 6 (1.5-fold) and
18 h (1.9-fold), but not at 2 h (1.3 fold). Such increased
SA levels by Mn21 probably indicate a loss of local
membrane integrity. To correct for differences in SA
tissue levels, DHBA levels are expressed as [DHBA/SA]
(mmol adduct/mol SA) followed by calculations of [ipsi-/
contralateral] ratios to determine the factor of increase
byMn21. [Ipsi-/contralateral] ratios of [DHBA/SA] were
significantly increased by Mn21 over time (P , 0.001),
reaching maximum levels at 6 h for both 2,3-DHBA
(4.1-fold increase) and 2,5-DHBA (6.9-fold increase)
and no significant increase between 0 and 2 h of
2,3-DHBA/SA ratios (Fig. 1).
DA levels (Fig. 1) were significantly decreased by
Mn21 at 2 h (253%) and declined further thereafter
until at least 18 h (265%) compared to contralateral
tissues (P , 0.001). Serotonin levels (Fig. 1) were signifi-
cantly decreased (249%) by Mn21 at 2 h and declined
further thereafter reaching the lowest levels at 18 h
(273% of contralateral striatum).
DOPAC (1.7-fold) and HVA (1.5- to 1.7-fold) levels
were significantly increased by Mn21 at 2 and 6 h and
were significantly decreased at 18 h (240% and 265%
of contralateral striatum, respectively). The resulting
DA turnover expressed as DOPAC/DA and HVA/DA
ratios was significantly elevated at 2 h (3.3- and
2.8-fold, respectively) and declined thereafter until a
still-significant increase of DOPAC/DA ratios (1.6-fold
of contralateral) and normal HVA/DA ratios at 18 h
(Fig. 2). 5-HIAA levels were significantly decreased
(239%) by Mn21 at 2 h and declined further thereafter
until 269% of contralateral tissue at 18 h. The result-
ing 5-HIAA/5-HT ratios were slightly, but significantly,
elevated by Mn21 (P , 0.001), but did not change
between 2, 6, and 18 h (Fig. 2).
In noninjected (contralateral) striatum, the means 6
SEM of 2,3- and 2,5-DHBA/SA values and DA, 5-HT,
238 SLOOT ET AL.
DOPAC, HVA, and 5-HIAA levels were respectively
0.30 6 0.033 and 2.03 6 0.11 mmol/mol SA and 68.9 6
1.43, 3.15 6 0.08, 5.16 6 0.16, 4.71 6 0.16, and 4.38 6
0.08 pmol/mg, except at 2 hwhere levels of DA, DOPAC,
and HVA were significantly elevated (P , 0.001). The
latter effect ismost likely due to chloralhydrate anesthe-
sia (Westerink, 1985).
Dose-Dependent Effects of Mn21 at 6 h
Six hours after intrastriatal injections of different
doses of Mn21 (0.13, 0.4, and 1.2 µmol), SA levels ex-
pressed as [ipsi-/contralateral] ratios were significantly
increased in a dose-dependent manner (P , 0.001) by
respectively 1.2-, 1.5-, and 2.0-fold. The [ipsi-/contralat-
eral] ratios of DHBA levels corrected for SA are shown
in Fig. 3. [2,3-DHBA/SA] values were significantly
increased by 0.4 and 1.2 µmolMn21 (P , 0.001), but not
by 0.13 µmol Mn21 or 0.4 µmol Mg21. [2,5-DHBA/SA]
values were significantly elevated by all doses, includ-
ing a relatively small increase by the control injection
withMg21 (137%), which is probably due tomechanical
damage by the injection needle. Both 2,3- and 2,5-
FIG. 1. Time course of 2,3- (triangles) and 2,5-DHBA (circles) formation corrected for SA (top) and of dopamine (squares) and serotonin
(diamonds) depletion (bottom) in striatum following a unilateral injection of 0.4 µmol Mn21 into striatum of SA-loaded rats (300 mg/kg ip; 2 h).
Data represent ipsi-/contralateral ratios of 6–7 rats per time point. All compounds changed time-dependently (P , 0.001, ANOVA).
Newman–Keuls post hoc multiple comparison tests (a 5 0.05) indicated significant changes between subsequent data time points (1/2) and
compared to zero time points (asterisks). The zero time points represent noninjected controls (treated only with SA). For comparison with
Mg21-injected controls at 6 h see Fig. 3.
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DHBA increases reached plateau levels by 0.4 µmol
Mn21 (respectively 4.2- and 6.9-fold).
DA levels (Fig. 3) were significantly reduced by 0.13
µmol Mn21 (215%), and declined dose-dependently to
287% by 1.2 µmol. Control injections with Mg21 in-
creased DA levels slightly, but significantly (114%;
P , 0.05). Serotonin levels (Fig. 3) were significantly
reduced by 0.13 µmol Mn21 (255%) and declined dose-
dependently until 276% of contralateral tissues
(P , 0.001). Following Mg21 injections, 5-HT levels
were slightly, but significantly, decreased (214%;
P , 0.05).
DOPAC and HVA levels were significantly increased
by 0.13 µmol Mn21 (respectively 1.9- and 2.4-fold) and
declined dose-dependently reaching levels of 251% and
232% at 1.2 µmol, respectively. Mg21 injections in-
creased DOPAC (161%) and HVA (188%) levels signifi-
cantly (P , 0.001). The resulting DOPAC/DA and
HVA/DA ratios were significantly increased in a dose-
dependent manner (P , 0.01), reaching 4.9- and 7.8-
fold elevations by 1.2 µmol Mn21, respectively (Fig. 4).
5-HIAA levels were significantly reduced by 0.13 µmol
Mn21 (241%) and declined dose-dependently until
276% (P , 0.001). The resulting 5-HIAA/5-HT ratios
were not dose-dependently changed by Mn21 (P 5 0.32)
(Fig. 4).
Detection of 6-OHDA after Mn21
In Mn21-injected striata of rats not loaded with SA,
no peaks at the position of 6-OHDA standards were
observed (data not shown).
Effect of Reserpine Pretreatment on Mn Neurotoxicity
The striatal DA and 5-HT contents of rats pretreated
with reserpine were depleted by 89 and 56%, respec-
tively. In reserpine-treated rats, Mn21 injections did not
significantly decrease DA levels any further compared
to contralateral tissues (P 5 0.39 by Student’s t test,
Fig. 5) in contrast to a significant further decrease of
5-HT levels until 276%. 2,3-DHBA/SA ratios were
significantly higher (P , 0.001) in both noninjected
(2.1-fold) and Mn21-injected striata (1.7-fold) of reser-
pine-treated rats compared to striata of control rats
(Fig. 5). A similar significant effect for 2,5-DHBA/SA
was observed in this respect (respectively 1.9- and
1.9-fold). The Mn21-induced 2,3-DHBA formation (ex-
pressed as ipsi-/contralateral ratios of DHBA/SA) in
reserpine-treated rats (2.8-fold) was not significantly
different from that in control rats (4.2-fold). The same
FIG. 2. Time course of dopamine and serotonin turnover follow-
ing unilateral intrastriatal injection of 0.4 µmol Mn21 into striatum
of salicylate-loaded rats (300 mg/kg ip; 2 h). Data represent [ipsi-/
contralateral] ratios of DOPAC/DA (circles), HVA/DA (triangles), and
5-HIAA/5-HT (squares) ratios of 6–7 rats per time point. The DA and
5-HT turnover changed time-dependently (ANOVA, P , 0.001). For
more details see legend to Fig. 1.
FIG. 3. Dose-dependent 2,3- and 2,5-DHBA formation corrected
for SA (top), and dopamine and serotonin depletions (bottom) in
striatum 6 h after a unilateral control (Mg21) or Mn21 injection (dose
as indicated) into striatum of SA-loaded rats. Data represent [ipsi-/
contralateral] ratios of 6–7 rats. All compounds changed dose-
dependently (ANOVA; P , 0.001). Newman–Keuls post hoc multiple
comparison tests (a 5 0.05) revealed significant changes between
subsequent dose points (1/2) and compared to the 0 dose group
(asterisk), which represents Mg21 injections (with 0.4 µmol). S,
significant difference between ipsi- and contralateral values using
Student’s t test (P , 0.05, only indicated for the zero dose group).
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was found for 2,5-DHBA formation in this respect
(respectively 6.5- versus 6.9-fold).
Effect of Mn21 on Total and LMW Iron in Striatum
Six hours after intrastriatal injection, Mn21 pro-
duced no significant changes in striatal LMW or total
iron pools compared to Mg21- or not-injected tissues
(Table 1). Furthermore, striatal LMW iron levels of
Mn21- or Mg21-injected rats were similar when mea-
sured under reducing or nonreducing conditions. In
contrast, 6 h after intrastriatal Fe21-injection, both
LMW and total iron pools in striatum were markedly
increased. In addition, in these striata, under reducing
conditions, about 15-fold more iron was chelated by
DFX in the LMW pool than in physiological medium.
This difference can be due to a fine ferric hydroxide
precipitation.
Effects of Deferoxamine on Mn Neurotoxicity
Co-injections of Mn21 with 0.2 or 2.0 nmol DFX into
striatum did not significantly alter 2,3- (Table 2) or
2,5-DHBA/SA increases or the extent of DA depletions
(Table 2) compared to Mn21 injections without DFX.
There were no significant effects of DFX in contralat-
eral tissues. Differences between ipsi- and contralat-
eral levels of 2,3-DHBA/SA, 2,5-DHBA/SA, and DA
were highly significant in all tested groups (P , 0.001).
The means 6 SEM of 2,3- and 2,5-DHBA/SA (mmol/mol
SA) and DA levels (pmol/mg) after NaCl injection were
respectively 0.40 6 0.03, 2.1 6 0.24, and 72.7 6 3.4.
DISCUSSION
The present studies using SA as a ·OH-trapping
agent demonstrate time- and dose-dependent ·OH for-
mation by Mn21 in the living brain. Furthermore, Mn
does not catalyze the Haber–Weiss reaction in vivo.
Additional experiments indicate that Mn21-induced
·OH are not generated as a result of DAoxidation nor by
an increase in (free) chelatable endogenous iron.
Pronounced increases of 2,3-DHBA/SA ratios (up to
4-fold) in Mn21-injected striatum compared to controls
(Figs. 1 and 3) suggest that Mn21 induces ·OH forma-
tion. In addition, our results indicate that ·OH are not
triggered by Mn itself, because maximum levels are
FIG. 4. Dose-dependent changes of dopamine and serotonin
turnover 6 h after a unilateral control (Mg21) or Mn21 injection (dose
as indicated) into striatum of salicylate-loaded rats (300 mg/kg ip; 2
h). Data represent [ipsi-/contralateral] ratios of [metabolite/neuro-
transmitter] ratios of 6–7 rats. DA turnover changed dose-depen-
dently (ANOVA;P , 0.005 for DOPAC/DAandP , 0.01 for HVA/DA),
whereas the 5-HT turnover did not. For more details see legend to
Fig. 3.
FIG. 5. Effect of pretreatment with reserpine (2.5 mg/kg ip; 24 h)
on 2,3-DHBA (mmol/mol SA; top) and dopamine levels (pmol/mg;
(bottom) in striatum 6 h after unilateral injection of 0.4 µmol Mn21
into striatum of SA-loaded rats (300 mg/kg ip; 2 h). Significant
differences between Mn21-injected (hatched bars) and noninjected
contralateral striata (C, white bars) are indicated by asterisks
(Student’s t test; P , 0.001). Both basal 2,3-DHBA/SA (noninjected
side) and increased 2,3-DHBA/SA by Mn21 were significantly higher
in reserpine-treated rats than in control rats (#, P , 0.001 by
Student’s t test). However, the increases of 2,3-DHBA/SA (expressed
as [ipsi-/contralateral] ratios) by Mn21 between reserpine-treated
(2.8-fold) and control rats (4.2-fold) were not significantly different
(P 5 0.16, Student’s t test). DA levels (bottom) were significantly
depleted by reserpine (not indicated, Student’s t test; P , 0.001).
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only reached after 6–18 h. The time course of 2,3-DHBA
formation after Mn21 is very different from that after
equimolar injections of Fe21 into striatum, where high-
est increases of 2,3-DHBA (10-fold) were observed after
30 min (57). Therefore, the present findings suggest
that Mn21 cannot catalyze the Haber–Weiss reaction in
vivo, which is supported by in vitro studies (1 and
references therein, 30).
DA and 5-HT depletions in striatum by Mn21 are
time- and dose-dependent and are not directly related
to ·OH formation (Figs. 1 and 3). In contrast to DA and
5-HT levels, 2,3-DHBA formation (ipsi-/contralateral
ratio of 2,3-DHBA/SA) was not significantly changed at
2 h and also did not change when the Mn21-dose was
increased from 0.4 to 1.2 µmol Mn21. This independent
action of Mn21 on these two processes was in line with
our subsequent studies with reserpine-treated rats.
Mn21-induced ·OH formation was not attenuated in the
DA-depleted striatum (Fig. 5). Furthermore, in the
reserpine-treated rat with 90% depletion of striatal DA,
Mn21 did not cause additional DA reduction. Thus,
Mn21-induced ·OH formation is independent of deple-
tion cq. oxidation of DA by Mn21. Indeed, in vitro
studies on the mechanism of Mn2/31-induced oxidation
of DA revealed that DA is rapidly and irreversibly
oxidized by Mn31 to its cyclized orthoquinone, resulting
in decreased levels of DA, but does not generate reac-
tive oxygen species since oxygen is neither consumed
nor required in this reaction (1, 51). In conclusion, a
similar process seems to occur in vivo. The twofold
elevation of basal ·OH production in striatum after
reserpine treatment (Fig. 5) is in line with another
study in which reserpine increased levels of oxidized
GSH in striatum, an indication of oxidative stress (58).
It has been suggested that toxic quinones as a
consequence of DA oxidation (by Mn) may compomise
cellular defense mechanisms against oxyradicals (51),
for instance by GSH depletion (26, 27, 38, 43). Our
results obtained at 6 h after Mn21 in reserpine-treated
rats do not support this hypothesis. However, an in-
crease of oxidative stress by quinones, and therefore a
role of DA in Mn neurotoxicity, cannot be ruled out at
later time points.
The increased production of another reactive oxygen
species, H2O2, due to enhanced enzymatic turnover of
DA (DOPAC/DA and HVA/DA ratios), which has been
hypothetically linked with oxidative stress (14, 58),
does not parallel 2,3-DHBA formation after Mn21 both
in time (Fig. 2) and with increasing dose (Fig. 4). This
indicates that not H2O2 production from enzymatic DA
oxidation, but other factors determine ·OH generation.
In addition, the serotonin turnover was only slightly
affected by Mn21, indicating a different (initial) re-
sponse of both types of neurons to Mn21 exposure.
TABLE 1
Effect of Intrastriatal Injection of 0.4 µmol Mn21, Fe21, or Mg21 (Controls) on Total Low (LMW)a or High Molecular
Weight (HMW) Iron (Fe21 1 Fe31) or Direct Chelatable LMW Ironb (Essentially Fe21) Levels in Striatum





Total iron levels (Fe21 1 Fe31)
LMWa HMW LMW 1 HMW
Noninjected ND 24 6 12 (3) 75 6 4 (3) 100 6 14 (3)
MgCl2 53 6 11 (4) 39 6 11 (3) 76 6 5 (7) 118 6 16 (3)
MnCl2 32 6 9 (4) 26 6 9 (4) 74 6 11 (8) 98 6 43 (4)
FeCl2 515 6 87 (5) 7247 6 1839 (4) 4958 6 274 (10) 12,500 6 290 (4)
Note. Data are means 6 SEM of 3–10 samples (n). Determinations of Mn21-, Mg21-, and noninjected striata are based on 2–4 pooled tissues
per sample. LMW and total iron levels in Mn21-injected striata were not significantly different from Mg21- or noninjected tissue. LMW iron
determined under bphysiological or areducing conditions (for details see Materials and Methods) were not significantly different in Mg21- or
Mn21-injected striata. In Fe21-injected striata, LMW and HMW iron pools were clearly increased. The difference between LMW iron levels
assessed in physiological and reduced media of Fe21-injected striata is probably due to a fine ferric hydroxide precipitate. ND, not determined.
TABLE 2
Effect of the Iron Chelator Deferoxamine (0, 0.2, or 2.0 nmol
DFX) on Mn21-Induced ·OH Formation (2,3-DHBA/SA) and
Dopamine Depletion 6 h after Co-injection of 0.4 µmol Mn21
with DFX into the Ipsilateral Striatum or 0.4 µmol NaCl with
DFX into the Contralateral Striatum of SA-loaded Rats




0.4 µmol MN21 and different
doses of deferoxamine (nmol)
0 0.2 2.0
2,3-DHBA/SA 1.92 6 0.12* 2.14 6 0.23* 1.85 6 0.06*
Dopamine 0.46 6 0.06* 0.47 6 0.02* 0.40 6 0.02*
Note. Data are means 6 SEM expressed as [ipsi-/contralateral]
ratios of 5–6 rats per dose. DFX co-injections did not significantly
changeMn21-induced 2,3-DHBA increases or DAdepletion (ANOVA).
Differences of 2,3-DHBA/SA values and DA levels between ipsi- and
contralateral striata were highly significant in the three groups.
*P , 0.001.
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Since Mn21 itself cannot trigger ·OH formation, and
the likely candidates DA and 6-OHDA—which we did
not detect in vivo—cannot explain the observed in-
crease of ·OH formation byMn21, the role of endogenous
iron was also examined after Mn21. However, in Mn21-
injected striatum LMW iron, which is considered a
relevant pool for catalyzing the Haber–Weiss reaction
(36), was not different from that inMg21- or noninjected
striata (Table 1). Results obtained in Fe21-injected
striata indicated that our assay procedures worked.
Thus, ‘‘free’’ or LMW iron does not participate in
Mn21-induced ·OH formation unless (very) local in-
creases play a role. Therefore intrastriatal co-injections
of Mn21 with the iron chelator DFX were conducted
using doses known to retard 6-OHDA neurodegenera-
tion (7) and sufficient to chelate the measured LMW
iron pool completely. However, different intrastriatal
DFX injections could not attenuate Mn21-induced 2,3-
DHBA formation (Table 2), which is consistent with our
data on LMW iron. An important additional fact which
supports the latter conclusion is that iron chelation by
DFX in large excess of Mn21 was not affected in vitro.
The question then arises, are there other mecha-
nisms whichmay be responsible for Mn21-induced ·OH?
We propose two othermechanisms. First,Mn21 accumu-
lates preferentially in mitochondria via the Ca21
uniporter, thereby inhibiting its own and Ca21 effluxes
(24) and impairing several mitochondrial respiratory
functions and GSH metabolism (9, 25, 38, 39). Under
such conditions, disturbances of cytochrome heme me-
tabolism (38, 49) and/or heme-associated electron trans-
fers by Mn21 may lead to oxoheme oxidants in the
presence of H2O2 or the postulated heme-associated
ferryl radicals (18, 28, 29, 48), which may cause SA
hydroxylation in our studies (48). DFX can probably not
chelate iron from heme proteins, and this may explain
the lack of an effect of DFX on Mn21-induced ·OH.
Recently, protection has been shown by NO-synthase
inhibitors after brain injury by some mitochondrial
toxins (52). Since Mn21 also acts like a mitochondrial
toxin that may raise NO, ·OH may be derived from the
decomposition of peroxynitrite, which is a reaction
product of NO and O2·2 (5, 15, 37, 34).
In conclusion, selective regional accumulation of
Mn21 in the basal ganglia and its preferential sequestra-
tion in mitochondria may lead to local oxyradical
formation andmitochondrial dysfunctions, which even-
tually result in selective cell death. The present studies
have shown that DAand chelatable iron do not contrib-
ute to Mn21-induced ·OH. Therefore, other mechanisms
explaining oxidant stress after Mn21 intoxication such
as site-specific ·OH formation through mitochondrial
heme–iron moieties or peroxynitrite formation should
be studied.An additional role of DAquinones in produc-
ing oxidative stress remains to be elucidated.
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